Harmony Biosciences Q3 2024 10-Q Filing
Ticker: HRMY · Form: 10-Q · Filed: 2024-10-29T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Harmony Biosciences filed its Q3 2024 10-Q. Financials and ops update.
AI Summary
Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details are presented in this quarterly report.
Why It Matters
This filing provides investors with an update on Harmony Biosciences' financial health and operational performance for the third quarter of 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — Quarterly reports can reveal significant financial shifts or operational challenges that impact stock value.
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241029 (date) — Date of filing
- 0001802665 (company) — Central Index Key for Harmony Biosciences Holdings, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on October 29, 2024.
What is the Central Index Key (CIK) for Harmony Biosciences Holdings, Inc.?
The CIK for Harmony Biosciences Holdings, Inc. is 0001802665.
What is the Standard Industrial Classification (SIC) code for Harmony Biosciences Holdings, Inc.?
The SIC code for Harmony Biosciences Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Harmony Biosciences Holdings, Inc.?
The fiscal year end for Harmony Biosciences Holdings, Inc. is December 31.
From the Filing
0001558370-24-013803.txt : 20241029 0001558370-24-013803.hdr.sgml : 20241029 20241029080042 ACCESSION NUMBER: 0001558370-24-013803 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241029 DATE AS OF CHANGE: 20241029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241402730 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-Q 1 hrmy-20240930x10q.htm 10-Q http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember 0001802665 --12-31 Q3 false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0 0 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-09-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-07-01 2024-09-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-09-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-07-01 2023-09-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-09-30 0001802665 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001802665 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001802665 us-gaap:RetainedEarningsMember 2024-09-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001802665 us-gaap:RetainedEarningsMember 2024-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001802665 2024-06-30 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-09-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001802665 us-gaap:RetainedEarningsMember 2023-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001802665 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2024-09-30 0001802665 us-gaap:CommonStockMember 2024-06-30 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2023-09-30 0001802665 us-gaap:CommonStockMember 2023-06-30 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-01-01 2024-09-30 0001802665 srt:MinimumMember 2023-01-01 2023-12-31 0001802665 srt:MaximumMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnits